INTRODUCTION {#s1}
============

The phosphatidylinositol-3-kinase (PI3K)/serine-threonine protein kinase AKT/mammalian target of rapamycin (mTOR) signaling pathway plays a crucial role in several cellular functions, including growth, differentiation, survival, and metabolism. Aberrations of this pathway are key drivers of carcinogenesis in many malignancies, and they are frequently implicated in both primary and acquired resistance to anticancer targeted therapies, as well as to cytotoxic agents and radiation ([@BRANNONMCS000620C7]). In particular, the activation of the PI3K/AKT/mTOR pathway has been indicated as a main mechanism of resistance to endocrine therapy in hormone receptor (HR)-positive breast cancers, and several studies suggest a mutual regulatory effect between PI3K/AKT/mTOR and estrogen receptor (ER) signaling ([@BRANNONMCS000620C15]).

The mTOR inhibitor everolimus (Afinitor/RAD001) was seen to significantly potentiate the activity and efficacy of the steroidal aromatase inhibitor exemestane in patients with HR^+^/HER2^--^ advanced breast cancers refractory to nonsteroidal aromatase inhibitors ([@BRANNONMCS000620C3]; [@BRANNONMCS000620C36]), and, thus, this combination has been approved as first-line treatment for this setting. However, evidence indicates that the inhibition of mTOR is not sufficient for achieving a complete blockade of the PI3K/AKT/mTOR pathway, given the numerous regulatory loops that provide potential escape mechanisms ([@BRANNONMCS000620C20]).

BEZ235 inhibits class I PI3K molecules and both mTORC1 and mTORC2 complexes. Preclinical models demonstrated that BEZ235 inhibited downstream molecules of mTOR, classic rapamycin-induced AKT activation, and tumor growth in xenografts ([@BRANNONMCS000620C30]). In dose-escalation trials of BEZ235, 20 of 27 patients undergoing FDG-PET (fluorodeoxyglucose-positron emission tomography) imaging demonstrated a decreased uptake, suggestive of some level of tumor shrinkage ([@BRANNONMCS000620C4]). [@BRANNONMCS000620C40] first showed that everolimus and BEZ235 had a synergistic effect in lung cancer cell lines and xenografts. Additional preclinical studies on multiple cancer models, including breast cancer, have confirmed this synergy and that the combination of subtherapeutic doses of everolimus synergized with BEZ235 to increase its potency more than 10-fold ([@BRANNONMCS000620C32]; [@BRANNONMCS000620C39]; [@BRANNONMCS000620C35]; [@BRANNONMCS000620C27]).

In this report, we describe a male breast cancer patient who was treated with the everolimus/BEZ235 combination therapy as third-line treatment for his metastatic disease and experienced a prolonged stable disease. Therefore, we investigated molecular mechanisms to explain the benefit and subsequent resistance to this combination treatment.

RESULTS {#s2}
=======

Clinical Presentation {#s2a}
---------------------

A 66-yr-old Caucasian man underwent a right radical mastectomy and sentinel lymph node biopsy for an infiltrative breast carcinoma of papillary histotype. Previous medical history included hypertension, carotid atherosclerosis, and diabetes mellitus. There was no family history of breast cancer or other cancers. The tumor was pT1c, N0/1, M0, R0, G2, Ki67 15%, ER^+^, PR^+^, HER2^--^. He started adjuvant tamoxifen treatment.

Two years later, multiple abnormal lymph nodes in the left axilla and a subcentimetric lesion with malignant features in the left mammary gland were detected. The patient underwent left radical mastectomy with axillary lymph node dissection (pretreatment sample). Histology revealed a stage IIIa infiltrative ductal carcinoma, pT1a, N+ 9/11, R0, Ki67 8%, ER^+^, PR^+^, HER2^--^. No distant metastases were detected. The patient was subsequently treated with standard adjuvant chemotherapy, consisting of four cycles of doxorubicin plus paclitaxel every 3 wk; followed by four cycles of cyclophosphamide, methotrexate, and 5-fluorouracil every 4 wk; and 5 wk of radiotherapy. Subsequently, he started adjuvant hormonotherapy with the nonsteroidal aromatase inhibitor letrozole.

The patient developed multiple nodal and bilateral lung metastases 13 mo later. Fine-needle aspiration was performed on the largest left axillary lymph node, confirming the recurrence of ductal breast carcinoma. The patient started 12 courses of first-line chemotherapy with vinorelbine plus capecitabine every 3 wk. Given the achievement of stable disease control by radiological assessments, the patient was shifted to maintenance hormonotherapy with high-dose estrogen receptor antagonist fulvestrant (500 mg i.m. every 4 wk). After 8 mo, the left axillary nodal metastases progressed.

The patient was treated by an investigational combination of BEZ235 (200 mg orally, twice daily) and subtherapeutic everolimus (2.5 mg orally, weekly). The combination therapy was generally well tolerated, except for a G3 skin rash developed likely as a cumulative toxicity after 16 mo of treatment. Standard everolimus dosing is 10 mg daily, whereas 300 mg b.i.d. is the maximum tolerated single-agent dose for BEZ235 ([@BRANNONMCS000620C4]). The combination treatment enabled sustained disease control for 18 mo.

When a new nodal metastasis occurred in the left infraclavicular region during continuous BEZ235/everolimus combination treatment, this treatment was discontinued and the infraclavicular lymph node underwent surgical biopsy (postprogression sample). Immunohistochemistry revealed the tumor as Ki67 10%--12%, ER^+^, PR^+^, and HER2^--^. The patient then started endocrine therapy with the steroidal aromatase inhibitor exemestane. Sixteen months later, a modest increase in the volume of left axillary lymph nodes was reported on computed tomography (CT) scan. The clinical history is depicted in [Figure 1](#BRANNONMCS000620F1){ref-type="fig"}.

![Clinical history of the patient. A 66-yr-old Caucasian man was diagnosed with infiltrative papillary breast cancer. While on tamoxifen, he developed a contralateral infiltrative ductal breast carcinoma (pretreatment sample). Following disease progression of his metastasis, he was treated with BEZ235 and everolimus. Stable disease was maintained for 18 mo. Upon nodal metastasis, treatment was discontinued and the postprogression sample collected.](BrannonMCS000620_F1){#BRANNONMCS000620F1}

Pharmacokinetics {#s2b}
----------------

A full pharmacokinetic (PK) profile of BEZ235 was collected from this patient with *C*~max~ (peak plasma concentration of the drug after administration), AUC (area under the curve), and *T*~1/2~ (elimination half-life) of 766 ng/mL, 6308 ng h/mL, and 5.53 h, respectively. The predose trough concentration (*C*~min~) of BEZ235 in plasma after 200 mg b.i.d. observed over the study period had values of 504, 262, 250, 75.4, and 363 ng/mL, respectively, for Period 1 Day 8 morning dose, Period 1 Day 8 evening dose, Period 2 Day 1 morning dose, Period 5 Day 1 morning dose, and Period 8 Day 1 morning dose. Everolimus *C*~min~ after weekly administration was near or below the limit of detection of the analytical method as expected based on the half-life of the drug of ∼30 hr.

Genomic Analyses {#s2c}
----------------

Genomic analysis was undertaken to attempt to understand why this patient sustained prolonged stable disease to the BEZ235/everolimus combination treatment and to better characterize male breast cancer (MBC), a rare disease (1% of all breast cancer cases). Therefore, whole-exome sequencing and analysis was performed on the pretreatment and postprogression samples and compared with a whole-blood normal control.

Overall, the tumors had few somatic alterations. Each tumor encoded 18 shared and nine private somatic short variants (point mutations or indels; [Table 1](#BRANNONMCS000620TB1){ref-type="table"}). All but two of the private short variants (*RNF212* p.L105S and *FUBP1* p.W537\*) were determined to be subclonal after adjusting for tumor purity and copy-number alterations. The tumors were also relatively stable at the chromosome level, sharing only a copy-number-neutral loss of heterozygosity in Chromosome 1p, gain of Chromosome 16p, and loss of Chromosome 16q.

###### 

Genomic variants detected by whole-exome sequencing

  Gene symbol   Chromo-some   HGVS DNA reference                          HGVS protein reference   Variant type     dbSNP/COSMIC ID   Comment        Pre-tx depth   Pre-tx allelic ratio   Post-tx depth   Post-tx allelic ratio   Normal depth   Normal allelic ratio
  ------------- ------------- ------------------------------------------- ------------------------ ---------------- ----------------- -------------- -------------- ---------------------- --------------- ----------------------- -------------- ----------------------
  *FUBP1*       Chr1          g.chr1:78422351C\>T                         p.W537\*                 Stop Gained      n/a               Pre-tx only    107            0.26                   132             0                       61             0
  *RNF212*      Chr4          g.chr4:1079732A\>G                          p.L105S                  Missense         n/a               Pre-tx only    99             0.32                   153             0                       94             0
  *RP1*         Chr8          g.chr8:55541441TC\>T                        p.S1667fs                Frameshift       n/a               Pre-tx only    125            0.04                   267             0                       163            0
  *CPXM2*       Chr10         g.chr10:125622146C\>T                       p.G166E                  Missense         n/a               Pre-tx only    39             0.08                   53              0                       49             0
  *CACNA1C*     Chr12         g.chr12:2788661C\>T                         p.R1704W                 Missense         rs373996684       Pre-tx only    184            0.18                   322             0                       175            0
  *ABCC9*       Chr12         g.chr12:22005137C\>A                        p.G888V                  Missense         n/a               Pre-tx only    72             0.18                   182             0                       102            0
  *NTS*         Chr12         g.chr12:86272172G\>A                        p.C62Y                   Missense         n/a               Pre-tx only    89             0.15                   266             0                       108            0
  *CACNA1H*     Chr16         g.chr16:1252074G\>A                         p.E542K                  Missense         n/a               Pre-tx only    58             0.07                   158             0                       35             0
  *AMFR*        Chr16         g.chr16:56396967G\>A                        p.R596C                  Missense         n/a               Pre-tx only    33             0.09                   29              0                       28             0
  *SPEN*        Chr1          g.chr1:16259731CCAGAAAACAACCCGAT\>C         p.QKTTRS2333fs           Frameshift       n/a               Both           138            0.35                   184             0.66                    122            0
  *SYT6*        Chr1          g.chr1:114640393C\>T                        p.A406T                  Missense         rs142164979       Both           61             0.23                   83              0.29                    42             0
  *ZDBF2*       Chr2          g.chr2:207175047G\>A                        p.R1932H                 Missense         COSM2150473       Both           173            0.21                   209             0.42                    145            0
  *YEATS2*      Chr3          g.chr3:183515744C\>T                        p.P1044L                 Missense         rs376025260       Both           70             0.21                   115             0.30                    58             0
  *CCDC71L*     Chr7          g.chr7:106300865T\>G                        p.S160R                  Missense         n/a               Both           13             0.23                   17              0.35                    15             0
  *KIAA1045*    Chr9          g.chr9:34971537G\>A                         p.R81Q                   Missense         rs374394658       Both           139            0.18                   173             0.39                    97             0
  *CCDC180*     Chr9          g.chr9:100092618C\>G                        p.P659A                  Missense         n/a               Both           107            0.26                   148             0.38                    93             0
  *CNNM1*       Chr10         g.chr10:101090101G\>C                       p.E319D                  Missense         n/a               Both           158            0.15                   189             0.35                    132            0
  *MICAL2*      Chr11         g.chr11:12278507A\>G                        p.D1044G                 Missense         n/a               Both           34             0.29                   50              0.36                    23             0
  *KDM4E*       Chr11         g.chr11:94760214A\>G                        p.N498S                  Missense         n/a               Both           69             0.13                   63              0.33                    35             0
  *TSPAN8*      Chr12         g.chr12:71526521A\>T                        p.D176E                  Missense         n/a               Both           182            0.18                   287             0.37                    180            0
  *CORO6*       Chr17         g.chr17:27942821C\>T                        p.V450M                  Missense         n/a               Both           122            0.25                   171             0.32                    92             0
  *AKAP1*       Chr17         g.chr17:55183750AGCTTGGATAGAAATGAGGAGG\>A   p.SLDRNEEG309S           Codon Deletion   COSM1244721       Both           151            0.11                   181             0.06                    84             0
  *NOTCH3*      Chr19         g.chr19:15280935A\>T                        p.W1721R                 Missense         n/a               Both           12             0.50                   12              0.25                    10             0
  *CPAMD8*      Chr19         g.chr19:17017774C\>T                        p.A1386T                 Missense         n/a               Both           148            0.23                   159             0.37                    104            0
  *ZNF420*      Chr19         g.chr19:37618255A\>G                        p.N121S                  Missense         n/a               Both           99             0.21                   244             0.35                    134            0
  *ZNF473*      Chr19         g.chr19:50550059A\>T                        p.R787\*                 Stop Gained      n/a               Both           180            0.26                   205             0.36                    135            0
  *KRTAP10-3*   Chr21         g.chr21:45978592T\>C                        p.T3A                    Missense         rs452472          Both           13             0.62                   7               0.43                    0              0
  *HTRA2*       Chr2          g.chr2:74757932T\>A                         p.L232Q                  Missense         n/a               Post-tx only   256            0.00                   225             0.23                    103            0
  *LRAT*        Chr4          g.chr4:155665556T\>A                        p.S26R                   Missense         n/a               Post-tx only   352            0                      235             0.03                    169            0
  *CREB3*       Chr9          g.chr9:35736430T\>G                         p.Y275D                  Missense         n/a               Post-tx only   87             0                      81              0.07                    68             0
  *ALOX5*       Chr10         g.chr10:45907697T\>G                        p.L164V                  Missense         n/a               Post-tx only   280            0                      219             0.05                    133            0
  *KNDC1*       Chr10         g.chr10:135013889G\>T                       p.E972\*                 Stop Gained      n/a               Post-tx only   87             0                      62              0.15                    45             0
  *SLITRK6*     Chr13         g.chr13:86368728T\>TA                       p.Y639Lfs                Frameshift       n/a               Post-tx only   278            0                      762             0.14                    175            0
  *PML*         Chr15         g.chr15:74336964G\>C                        p.R755P                  Missense         n/a               Post-tx only   471            0                      363             0.07                    235            0
  *ARHGAP35*    Chr19         g.chr19:47423891GC\>AA                      p.P654T                  Missense         n/a               Post-tx only   217            0                      179             0.13                    109            0
  *RRP1*        Chr21         g.chr21:45213265C\>T                        p.R114C                  Missense         n/a               Post-tx only   196            0                      136             0.14                    83             0

HGVS, Human Genome Variation Society; dbSNP, Database of Single Nucleotide Polymorphisms; COSMIC, Catalogue of Somatic Mutations in Cancer; Pre-tx, pretreatment sample; Post-tx, postprogression sample; n/a, not applicable.

Although there was no family history of breast cancer, we examined *BRCA1* and *BRCA2* for genomic alterations given that the patient developed two histologically distinct cases of breast cancer. No somatic alterations were detected in either gene, but three germline missense mutations were identified: *BRCA1* p.Q309R, *BRCA2* p.V2466R, and *BRCA2* p.N372H. None are clear breast cancer susceptibility loci; however, certain contradictory studies have suggested that these *BRCA2* polymorphisms may or may not confer increased risk ([@BRANNONMCS000620C16]; [@BRANNONMCS000620C34]; [@BRANNONMCS000620C11]; [@BRANNONMCS000620C41]).

We assessed the mutations noted in [Table 1](#BRANNONMCS000620TB1){ref-type="table"} in the context of the targeted pathway and previously reported alterations. No somatic mutations or copy-number variants were identified in genes encoding members of the PI3K/mTOR pathway, such as *PIK3CA*, *PTEN*, *MTOR*, *TSC1*, or *TSC2*. Gene or chromosomal region alterations previously uncovered by other studies ([@BRANNONMCS000620C17]; The [@BRANNONMCS000620C8]; [@BRANNONMCS000620C18]), such as *TP53*, *KRAS*, 8q gain, 11q gain, 17q gain, 20q gain, or 9q loss, were absent in this patient. Only two of the identified short variants (point mutations or indels) were previously reported in the COSMIC database, but with not more than two supporting records each. Of the 36 total genes with point mutations or indels, only *SLITRK6* and *CACNA1C* were also mutated in the 10 MBC patients from the Cancer Genome Atlas (TCGA; [@BRANNONMCS000620C8]); however, the impact of these genes on cancer is unclear.

Three of the somatic variants were of greater interest, however. One of the shared short variants was a 16-bp frameshift deletion in the Msx2-binding domain of *SPEN*, which encodes a potential negative regulator of estrogen receptor (ER) transcriptional activity ([@BRANNONMCS000620C38]). The pretreatment sample had a private nonsense mutation in *FUBP1*, a gene commonly mutated in lower-grade gliomas ([@BRANNONMCS000620C9]). The postprogression sample also had a 9-megabase loss in Chromosome 12p (Supplemental Fig. S1), which contains the tumor suppressor p27Kip1 (encoded by *CDKN1B*).

Protein Expression Analyses {#s2d}
---------------------------

To determine whether important signaling molecules were being regulated at the protein level, immunohistochemistry (IHC) was performed on the pretreatment and postprogression tumor samples (Supplemental Data). The examined signaling pathway biomarkers (HER2, PTEN, pAKT, pS6-235/235, pS6-240/244, pMAPK, pMEK, and pEGFR) presented no or minimal expression changes between the two tumor specimens. These results suggest that these proteins were noncontributory in the tumor\'s resistance to the BEZ235/everolimus combination therapy. Despite no differences between the time points, overall expression of phosphorylated ribosomal protein S6 at Ser240/244, a downstream target of mTORC1, in both samples was moderate (H-score 140).

Hormone receptor status was also evaluated for this patient. IHC indicated low ER/PR expression (ER 30% 1^+^; PR 20% 1^+^, 10% 3^+^) in the pretreatment sample, but expression levels of both receptors were increased (60% 1^+^) in the postprogression sample. Analysis of these samples using the more quantitative Automated Quantitative Analysis (AQUA) IHC technology platform verified a 10-fold score increase of ER from 31 to 312 and an almost fivefold increase of PR from 271 to 1305 ([Fig. 2](#BRANNONMCS000620F2){ref-type="fig"}).

![AQUA quantitative immunohistochemistry showed a 10-fold increase in estrogen receptor (ER) (*A*) and an almost fivefold increase in progesterone receptor (PR) (*B*) between the pretreatment and postprogression samples. HER2 expression remained negative in both samples. The graphs below the image display the AQUA scores. The gray box indicates the cutoff, the green arrow, the pretreatment score, and the red arrow, the postprogression score. Microscopy images at 40× magnification.](BrannonMCS000620_F2){#BRANNONMCS000620F2}

DISCUSSION {#s3}
==========

MBC is a rare disease, with only 2350 estimated new cases and 440 deaths in the United States in 2015, ∼1% of female breast cancer and \<0.5% of male cancer overall ([@BRANNONMCS000620C2]). Because of its infrequency, the treatment and genetics of MBC is not as well understood as for females.

Here we described a male breast cancer patient who received combination therapy of the dual PI3K/mTOR inhibitor BEZ235 and low-dose everolimus as a third-line treatment for his metastatic ductal carcinoma. This treatment yielded stable disease for 18 mo before progression. Therefore, we chose to pursue genomic and immunohistochemical analyses to understand the molecular mechanism of this sensitivity and subsequent resistance, as well as the underlying genetics of MBC.

Because of the extended stable disease the patient sustained from the PI3K/mTOR inhibitors, we had hypothesized that genomic and/or protein expression alterations in this pathway would suggest a clear biological explanation. The results, though, did not suggest hyperactivation of this pathway in the patient\'s tumor prior to the BEZ235/everolimus combination therapy. This lack of obvious hyperactivation could potentially be due to the pretreatment sample being from initial diagnosis of the invasive ductal carcinoma, before the development of detectable metastases and the several additional lines of therapy prior to the combination treatment. However, previous research has demonstrated that PI3K pathway alterations are not necessary for response to PI3K or mTOR inhibitors ([@BRANNONMCS000620C25]; [@BRANNONMCS000620C23]), reinforcing that the clinical benefit from PI3K or mTOR inhibition is not dependent on PI3K pathway hyperactivation. Nevertheless, there was moderate expression of the mTORC1-specific phosphorylation of ribosomal protein S6, suggesting that this pathway may be active in the tumors. Additionally, the tumor had a very quiet copy-number profile, which has been associated in general with better prognosis ([@BRANNONMCS000620C33]; [@BRANNONMCS000620C6]; [@BRANNONMCS000620C1]). In the BOLERO-2 clinical trial in HR^+^/HER2^−^ metastatic female BC patients, patients with lower chromosomal instability had increased progression-free survival gain from everolimus treatment ([@BRANNONMCS000620C23]). Therefore, although there is no clear genomic or protein biomarker explanation for the patient\'s sensitivity to the BEZ235/everolimus combination therapy, the patient\'s HR positivity and chromosomal stability correspond similarly with response to other PI3K or mTOR inhibition in female BC patients.

To explain the tumor\'s subsequent resistance to the combination PI3K/mTOR inhibition, genomic and histological examination revealed both the loss of a tumor suppressor and increased expression of the hormone receptors as potential contributing factors. The loss of a 9-megabase region of Chromosome 12p in the postprogression tumor included the cell cycle inhibitor p27Kip1, a protein normally inhibited by the PI3K pathway. Therefore, deletion of one copy of the gene may have partially released the inhibition on cell proliferation that occurred because of up-regulation of p27Kip1 from shutting down the PI3K pathway. Supporting this notion, previous research has shown that the level of p27Kip1 expression correlates with response to BEZ235 in mouse embryo fibroblasts ([@BRANNONMCS000620C26]). Additionally, immunohistochemistry detected a five- to 10-fold increase in hormone receptors in the postprogression sample, compared with the pretreatment sample. Resistance associated with an increase in hormone receptor levels has been seen in a number of patients treated with a PI3Kα inhibitor, and in vitro work revealed that suppression of the PI3K pathway increases transcription of *ESR1* and expression of ER ([@BRANNONMCS000620C5]). The patient\'s tumor\'s renewed dependence on the hormone receptors is supported by further disease control upon treatment with the aromatase inhibitor exemestane. Therefore, the decrease of cell cycle inhibition combined with an increase in ER and PR levels may have been enough to abrogate the effect of the PI3K/mTOR pathway blockade by BEZ235/everolimus.

To better understand the genomics of sporadic MBC, we profiled the patient\'s pretreatment and postprogression tumors and found 27 short variants detected in each sample, gain of Chromosome 16p, and loss of Chromosome 16q. No mutations were found in the common breast cancer genes *PIK3CA*, *TP53*, *CDH1*, *GATA3*, or *MAP3K1*; no overlap was discovered with common alterations from the 10 reported MBC cases by TCGA; and no high-level amplifications of oncogenes were detected. Although the contribution of most of the identified genomic alterations are unclear, the shared *SPEN* 16-bp frameshift deletion may be biologically relevant: Previous research suggests that *SPEN* is a negative regulator of ER transcriptional activity whose expression is increased in the presence of estradiol, creating a potential self-regulatory loop for the estrogen response ([@BRANNONMCS000620C38]). The loss of function of this repressor could therefore potentially allow for increased ER transcriptional activity in this ER-positive tumor. Additionally, the nonsense mutation in *FUBP1* in the localized pretreatment tumor is interesting because loss-of-function mutations are common in lower-grade gliomas ([@BRANNONMCS000620C9]); however, its role in breast cancer is unknown. Overall, however, the relatively quiet genomes suggest that the patient\'s tumors could be driven by transcriptional, epigenetic, and/or cell signaling mechanisms, particularly those related to hormone receptors.

In conclusion, genomic and histological examination of this MBC patient with prolonged stable disease while under BEZ235/everolimus combination treatment has given us further insight into both MBC and response/resistance to this treatment. Additional studies will be necessary to understand the role of FUBP1 inactivation in MBC and to confirm the hypothesis of decreased p27Kip1 expression and increased hormone receptor expression as a mechanism of resistance to PI3K inhibitors.

METHODS {#s4}
=======

Clinical Assessment {#s4a}
-------------------

The patient had tumor assessments by CT scan every 8 wk from the start of BEZ235/everolimus combination treatment until disease progression. The patient had weekly visits for clinical examination during the first 8 wk of treatment; thereafter, the patient returned for visits every 28 d.

Pharmacokinetics {#s4b}
----------------

A full PK profile of BEZ235 was collected in this patient at Cycle 1 Day 8. Concentration of BEZ235 in plasma was determined by a LC-MS/MS (liquid chromatography--tandem mass spectrometry) method following protein precipitation. The method has an LLOQ (lower limit of quantification) of 2.0 ng/mL. Everolimus blood concentration in whole blood (K2 EDTA) was determined by the LC-MS/MS method following solid-phase extraction. The method has an LLOQ of 0.300 ng/mL. PK parameters were calculated using noncompartmental methods.

Immunohistochemistry Assays {#s4c}
---------------------------

During treatment, formalin-fixed paraffin-embedded (FFPE) slides were stained and reviewed by a certified pathologist at the University of Verona. Pretreatment and postprogression results were further validated for this study. HER2 negativity was confirmed via IHC by ARUP Laboratories. FFPE slides were stained and expression of Ki-67, pMAPK, pEGFR, pMEK, pAKT, pS6-235/236, pS6-240/244, and PTEN was assessed by a certified pathologist. ER and PR expression was confirmed and quantified using AQUA technology (Genoptix); Fluorescent antibodies were bound, digitized using the slide-scanner system, and measured based on nuclear expression in tumor cells.

Genomic Sequencing and Analysis {#s4d}
-------------------------------

Tumor purity of pretreatment and postprogression tumor FFPE sections was pathologically estimated at 85% and 75%, respectively. DNA was extracted from FFPE and whole-blood control samples using the Promega Maxwell DNA extraction kit. Libraries were constructed using Illumina TruSeq, captured with the Agilent SureSelect Whole Exome V4 baits and protocol, and sequenced on an Illumina HiSeq 2500 as 100-bp paired-end reads. Resulting FASTQ files were aligned to the hg19 reference genome using BWA-MEM ([@BRANNONMCS000620C28]), duplicates were marked with Picard (<http://broadinstitute.github.io/picard/>), and local realignment and base quality recalibration were performed with GATK (Genome Analysis Toolkit; [@BRANNONMCS000620C31]; [@BRANNONMCS000620C19]). Resulting mean target coverage of the pretreatment and postprogression FFPE tumor specimens were 142× and 179×, respectively ([Table 2](#BRANNONMCS000620TB2){ref-type="table"}). The whole-blood control normal control was purposely sequenced to a lower coverage of 82×.

###### 

Sequencing metrics

  Sample            Total reads   Unique mapped reads   Mean target coverage
  ----------------- ------------- --------------------- ----------------------
  Pretreatment      118,318,058   92,907,513            142
  Postprogression   137,438,824   120,704,547           179
  Normal            59,691,734    56,623,598            82

Single-nucleotide variants were called in paired normal mode using MuTect ([@BRANNONMCS000620C13]) and phased with GATK, whereas indels were called with Pindel ([@BRANNONMCS000620C42]) and filtered against a pool of normal samples. Annotation was performed with SnpEff ([@BRANNONMCS000620C14]), using dbSNP v141 (<http://www.ncbi.nlm.nih.gov/SNP/>), COSMIC v70 ([@BRANNONMCS000620C21]), and dbNSFP v2.4 ([@BRANNONMCS000620C29]). Nonsynonymous protein-coding SNVs or indels with coverage of at least 10× or 30×, respectively, in at least one tumor sample were retained. All calls were manually reviewed in IGV (Integrative Genomics Viewer; [@BRANNONMCS000620C37]). Copy number, tumor purity, loss of heterozygosity, and subclonality were performed using an in-house implementation, the ABSOLUTE algorithm ([@BRANNONMCS000620C10]), after the GC normalization step from Control-FREEC ([@BRANNONMCS000620C24]). Tumor purity was calculated to be 47% in the pretreatment sample and 72% in the posttreatment sample. Common alterations in the 10 MBC patients from the BRCA TCGA study were accessed via the Breast Invasive Carcinoma (TCGA, Provisional) data set at <http://cBioPortal.org> ([@BRANNONMCS000620C12]; [@BRANNONMCS000620C22]).

ADDITIONAL INFORMATION {#s5}
======================
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The treatment of this patient in the clinical trial was approved by the University of Verona\'s Institutional Review Board and conducted in accordance with Good Clinical Practice, the Declaration of Helsinki, and other applicable local regulations. The patient provided written informed consent for sequence analysis.

Database Deposition and Access {#s5b}
------------------------------

The somatic short variants (point mutations and indels), *BRCA* germline variants, copy number alterations, and LOH regions for both the pretreatment and postprogression samples (Supplemental Table 2) identified in this study have been deposited in ClinVar (<http://www.ncbi.nlm.nih.gov/clinvar/>) under accession numbers SCV000258645--SCV000258901. Permission has not been granted for deposition of sequencing data.
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